AARD Stockholders Have Rights – If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and May 14, 2026 (the "Class Period"). Aardvark is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies designed to inhibit hunger and treat metabolic diseases such as Prader-Willi Syndrome (“PWS”), a neurodevelopmental disorder condition that presents hyperphagia, or a feeling of extreme, insatiable hunger.

The complaint alleges that Aardvark misled investors regarding the viability and efficacy of its lead drug candidate ARD-101.

Investors who suffered significant losses during the Class Period may be eligible to participate in the lawsuit and should contact Robbins LLP for information about becoming lead plaintiff before the October 13, 2026 deadline.

Listen to our podcast.

Why Was Aardvark Therapeutics Sued?

The complaint alleges that the Company’s lead product candidate is ARD-101, which defendants have repeatedly described as a “gut-restricted” small-molecule agonist of certain TAS2Rs expressed in the gut lumen. To evaluate the effect of ARD-101on hyperphagia-related behavior in patients with Prader-Willi Syndrome, defendants commenced both a Phase 3 clinical trial, referred to as the HERO trial, and an open-label extension.

The Offering Documents in support of the IPO informed investors that the preclinical data concerning ARD-101 "suggest that ARD-101 shows potential to be a well-tolerated, satiety-inducing drug."

Notwithstanding, the complaint alleges that defendants failed to disclose that:

1. ARD-101 was less safe than defendants had led investors to believe;
2. accordingly, ARD-101’s clinical, regulatory, and commercial prospects were overstated; and
3. as a result, defendants’ public statements were materially false and misleading at all relevant times.

Why Did AARD Stock Drop?

The complaint alleges that on February 27, 2026, Aardvark issued a press release “announc[ing] it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial.” Aardvark attributed the decision to “reversible cardiac observations at above target therapeutic doses found during routine safety monitoring in a healthy volunteer study” and said that it “has voluntarily paused ongoing enrollment and dosing in the HERO trial” while “conducting a comprehensive review of the data to inform next steps.” On this news, Aardvark’s stock price fell $7.02 per share, or 56.2%, to close at $5.47 per share on March 2, 2026.

Schreibe Deinen Kommentar